there is an unmet need for new treatments for autoimmune diseases that transform paradigms and clinical practice. landos will address that unmet clinical need. we know physicians are tired of settling for mediocre therapies for patients living with autoimmune disorders. with one first in class, oral therapy for inflammatory bowel disease (ibd) and its two clinical manifestations: crohn’s disease and ulcerative colitis, showing remarkable preclinical results and entering clinical trials, our team is poised to soon offer ibd patients a better way. the bottom line is this: patients deserve treatment options that are safer, more effective, and less disruptive to their lives. that is what drives landos scientists and our team each and every day.